The British Society for Rheumatology Biologics Register
Open Access
- 1 November 2005
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 64 (suppl_4), iv42-iv43
- https://doi.org/10.1136/ard.2005.042499
Abstract
The British Society for Rheumatology (BSR) established a nationwide register for patients with rheumatological disorders treated with biologic agents. The register is designed as a national prospective study whose primary purpose is to assess long term toxicity from the use of these agents in routine practice. In addition, the data will be capable of addressing the benefits from their use in relation to their toxicity. One specific feature of the BSR register is the recruitment and collection of data from a parallel comparison group, comprising patients with active rheumatoid arthritis treated with conventional disease modifying agents. Both class specific and drug specific analyses of the group treated with biologicals are planned.Keywords
This publication has 5 references indexed in Scilit:
- Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patientsArthritis & Rheumatism, 2004
- Rheumatoid arthritis and malignant lymphomasCurrent Opinion in Rheumatology, 2004
- Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relativesArthritis & Rheumatism, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ, 1998